Herbal Formula Science (대한한의학방제학회지)

The Korean Medicine Society for the Herbal Formula Study (대한한의학방제학회)
권호 표지
DOI QR코드

DOI QR Code

Eriobotrya japonica inhibits the transactivation of nuclear orphan receptor : the possibility to treat the chronic diseases

비파엽의 핵수용체 관련 신규 약물 작용점 연구 : 만성 질환 치료 가능성

  • Min-Jin, Kim (School of Korean Medicine, Dongguk University) ;
  • Young Woo, Kim (School of Korean Medicine, Dongguk University) ;
  • Sun-Dong, Park (School of Korean Medicine, Dongguk University)
  • 김민진 (동국대학교 한의학과 방제학교실) ;
  • 김영우 (동국대학교 한의학과 방제학교실) ;
  • 박선동 (동국대학교 한의학과 방제학교실)
  • Received : 2022.08.10
  • Accepted : 2022.08.31
  • Published : 2022.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : Oxidative damage has a variety of mechanism in the human organs including brain and liver. The purpose of this study is to examine the prevention against cellular damage, and the inhibitory effect on lipogenesis of the water extract of Eriobotrya japonica (EJE). Methods : The effect of EJE on cell viability was assessed using the MTT assay. To investigate the mechanism of EJE's inhibition of lipogenesis, we analyzed the relevant proteins using immunoblot analysis. Results : Induction of T0901317, a LXR agonist, significantly increased SREBP-1c expression, which was blocked by the pretreatment of EJE in the dose-dependent manners. This beneficial herb also regulated the genes related with SREBP-1c such as the acetyl-CoA carboxylase. Conclusion : These results suggested that EJE might have a possibility of the treatment of chronic diseases as mediated with the inhibition of LXRα/SREBP-1c pathway.

Keywords

Acknowledgement

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (number: HF20C0212) and (number: HF21C0061).

References

  1. Park YC, Park HM, Lee SD. Inducible Mechanisms for Hepatotoxicity caused by Traditional Korean Medicines in a view of Toxicology. Journal of Korean Medicine. 2011;32(4);48-67.
  2. Chung KW. Ultrastructure of chronic liver diseases: From light to electron microscopy. Clinical and Molecular Hepatology. 2002;8(1):112-123.
  3. Yoon SK. Diagnosis and treatment of fatty liver. Korean Journal of Medicine. 2009;76(6):677-679.
  4. Kim CY, Moon SM, Hyun KY, Kim DS, Choi SC. Difference in Serum Iron, Cardiac, and Biochemical Indices between Alcoholic and Non-alcoholic Fatty Liver. Journal of Life Science. 2009;19(2):185-191. https://doi.org/10.5352/JLS.2009.19.2.185
  5. Brunt EM. Pathology of fatty liver disease. Modern Pathology. 2007;20(1):S40S48.
  6. Choi HS, The Steroid Receptors: Molecular Mechanism of Action. Korean Endocrine Society. 2000;15(3).
  7. Lee EK, Park YJ. Metabolic regulation of nuclear receptors. Journal of Korean Endocrine Society. 2008;23(3):155-164. https://doi.org/10.3803/jkes.2008.23.3.155
  8. Bae YI, Seo KI, Park SK, Shim KH. Loquat (Eriobotrya japonica Lindl.) Leaf Tea Processing and Its Physicochemical Properties. Korean J. Postharvest Sci Technol. 1998;5(3):262-269.
  9. Kim SJ, Park JO, Park SN. Antioxidative Effect and Component Analysis of Eriobotrya japonica Leaf Extracts. J Soc. Cosmet. Sci. Korea. 2012;38(1):57-65. https://doi.org/10.15230/SCSK.2012.38.1.057
  10. Kim SM, Kim AY, Lee KI. Nitric Oxide Production Inhibitory Effects of Three Caffeoylquinic Acids Isolated from Hot Water Extract of Eriobotrya japonica L. Leaves. Korean J. Medicinal Crop Sci. 2020;28(4):245-253. https://doi.org/10.7783/KJMCS.2020.28.4.245
  11. Lee H, Kim YK, Lee HJ, Lee JJ. Effects of Loquat (Eriobotrya japonica Lindl.) Ethanol Extracts of Different Aerial Parts on Antioxidant Activity and Antiproliferation of Human Cancer Cells. Korean J Community Living Sci. 2016;27(2):211~220. https://doi.org/10.7856/kjcls.2016.27.2.211
  12. De Tommasi N, De Simone F, Pizza C, Mahmood N, Moore PS, Conti C et al. Constituents of Eriobotrya japonica. A Study of Their Antiviral Properties. J. Nat. Prod. 1992;55(8):1067-1073. https://doi.org/10.1021/np50086a006
  13. Lee WK, Choi YY, Yang WM. Effect of Eriobotrya folium on Local Fat via Regulation of Lipase Secretion. Journal of Korean Medicine for Obesity Research. 2017;17(2):101-110. https://doi.org/10.15429/jkomor.2017.17.2.101
  14. Yun UJ, Bae SJ, Song YR, Kim YW. A Critical YAP in Malignancy of HCC Is Regulated by Evodiamine. Int J Mol Sci. 2022 Feb 6;23(3):1855.
  15. Beltowski J. Liver X receptors (LXR) as therapeutic targets in dyslipidemia. Cardiovasc Ther. 2008;26(4):297-316. https://doi.org/10.1111/j.1755-5922.2008.00062.x
  16. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro1 JMA, Shimomura I, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ. Genes & Dev. 2000;14(22):2819-2830. https://doi.org/10.1101/gad.844900
  17. Apfel R, Benbrook D, Lernhardt E, Ortiz MA, Salbert G, Pfahl M. A Novel Orphan Receptor Specific for a Subset of Thyroid Hormone-Responsive Elements and Its Interaction with the Retinoid/Thyroid Hormone Receptor Subfamily. Molecular and cellular biology. 1994;14(10):7025-7035. https://doi.org/10.1128/MCB.14.10.7025
  18. Song C, Kokontis JM, Hiipakka RA, Liao S. Ubiquitous receptor: A receptor that modulates gene activation by retinoic acid and thyroid hormone receptors. Proc. Nati. Acad. Sci. 1994;91(23):10809-10813. https://doi.org/10.1073/pnas.91.23.10809
  19. Ferre P, Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes, Obesity and Metabolism. 2010;12(s2):83-92. https://doi.org/10.1111/j.1463-1326.2010.01275.x
  20. Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. In J. Molecular Medicine. 2008;21(4);507-511.
  21. Yap F, Craddock L, Yang J. Mechanism of AMPK Suppression of LXR-dependent Srebp-1c transcription. Int J Biol Sci. 2011;7(5):645-650. https://doi.org/10.7150/ijbs.7.645
  22. Ferre P, Phan F, Foufelle F. SREBP-1c and lipogenesis in the liver: an update. Biochem J. 2021;478(20):3723-3739. https://doi.org/10.1042/BCJ20210071
  23. Yin W, Mu J, Morris JB. Role of AMP-activated Protein Kinase in Cyclic AMP-dependent Lipolysis In 3T3-L1 Adipocytes. Journal of Biological Chemistry. 2003;278(44):43074-43080. https://doi.org/10.1074/jbc.M308484200
  24. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumor suppression. Nat Rev Cancer. 2009;9(8):563-575. https://doi.org/10.1038/nrc2676
  25. Mhairi C Towler, D Grahame Hardie. AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling. Circ. Res. 2007;100(3):328-341. https://doi.org/10.1161/01.RES.0000256090.42690.05
  26. Hardie DG. The AMP-activated protein kinase pathway - New players upstream and downstream. Journal of Cell Science. 2004;117(23):5479-5487. https://doi.org/10.1242/jcs.01540
  27. Dogliotti G, Kullmann L, Dhumale P, Thiele C, Panichkina O, Mendl G, et al. Membrane-binding and activation of LKB1 by phosphatidic acid is essential for development and tumour suppression. Nature Communications. 2017;8(1):1-12. https://doi.org/10.1038/s41467-016-0009-6